Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate.

IF 4.7 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2026-09-28 DOI:10.1007/s12325-026-03801-2

Becky Bosley, Isabelle Wlodkowski, Donna Catamero, Sarah Meredith

{"title":"Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate.","authors":"Becky Bosley, Isabelle Wlodkowski, Donna Catamero, Sarah Meredith","doi":"10.1007/s12325-026-03801-2","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma is a malignant hematologic disorder characterized by the proliferation of abnormal plasma cells in the bone marrow. Although improvements in survival as novel therapies have become available, almost all patients who receive multiple myeloma therapies will relapse. Patients experience physical and emotional impacts from both multiple myeloma and its treatment as they progress through periods of remission and relapse. It is essential to support patients throughout their disease with holistic management, underpinned by collaboration among the clinical team and emotional support resources, including access to patient support groups. This article is co-authored by a person living with multiple myeloma, along with a dietitian specializing in cancer dietetics, a nurse practitioner who cares for patients with multiple myeloma at a large academic center, and a patient advocate at the International Myeloma Foundation. Written from a first-person perspective, the patient describes her journey of living with multiple myeloma and her current treatment with talquetamab, with added perspectives from clinical and patient advocacy experts.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-026-03801-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Multiple myeloma is a malignant hematologic disorder characterized by the proliferation of abnormal plasma cells in the bone marrow. Although improvements in survival as novel therapies have become available, almost all patients who receive multiple myeloma therapies will relapse. Patients experience physical and emotional impacts from both multiple myeloma and its treatment as they progress through periods of remission and relapse. It is essential to support patients throughout their disease with holistic management, underpinned by collaboration among the clinical team and emotional support resources, including access to patient support groups. This article is co-authored by a person living with multiple myeloma, along with a dietitian specializing in cancer dietetics, a nurse practitioner who cares for patients with multiple myeloma at a large academic center, and a patient advocate at the International Myeloma Foundation. Written from a first-person perspective, the patient describes her journey of living with multiple myeloma and her current treatment with talquetamab, with added perspectives from clinical and patient advocacy experts.

查看原文本刊更多论文

复发/难治性多发性骨髓瘤患者、执业护士、营养师和患者倡导者的生活视角和多学科护理。

多发性骨髓瘤是一种恶性血液系统疾病，其特征是骨髓中异常浆细胞的增殖。虽然新的治疗方法可以改善生存，但几乎所有接受多发性骨髓瘤治疗的患者都会复发。多发性骨髓瘤及其治疗对患者的身体和情绪都有影响，因为他们经历了缓解期和复发期。至关重要的是，在整个疾病过程中，通过临床团队之间的合作和情感支持资源，包括与患者支持小组的接触，为患者提供全面的管理支持。本文由一名多发性骨髓瘤患者、一名专攻癌症营养学的营养师、一名在大型学术中心照顾多发性骨髓瘤患者的执业护士和国际骨髓瘤基金会的患者倡导者共同撰写。作者以第一人称的视角描述了她与多发性骨髓瘤的生活历程，以及她目前使用talquetamab的治疗，并从临床和患者倡导专家的角度进行了补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.